SueWallSt Reminds Park Ha Biological Technology Co. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 28, 2026

A securities class action was filed against Park Ha Biological Technology (NASDAQ: BYAH) over alleged omissions related to its sub-5% IPO public float and an alleged pump-and-dump promotion scheme. BYAH shares collapsed $38.02, or approximately 93%, to $2.99 on July 8, 2025, erasing more than $1 billion of market capitalization. The suit names the company, CEO Xiaoqiu Zhang, CFO/director Xiaoyan Zhu, and director Li Wang, alleging violations of Securities Act and Exchange Act provisions.

Analysis

This is not a new operating-data catalyst; it is a plaintiff-firm solicitation tied to a historical collapse, so incremental fundamental information is limited. The actionable implication is instead liquidity: a micro-cap with prior extreme dislocation, governance allegations, and likely constrained institutional sponsorship can remain structurally uninvestable, with episodic retail-driven rallies creating short-lived rather than durable repricing opportunities.

For BYAH, litigation raises the probability of higher D&O costs, management distraction, auditor/financing friction, and potential exchange-compliance risk over the next 6-18 months. More important than the eventual damages outcome is whether the company can file timely audited financials, maintain a credible auditor, and demonstrate independently verifiable revenue and cash conversion; failure on any of these can impair access to equity capital well before a court ruling.

The contrarian case is that the stock already discounts severe governance risk and that the lawsuit itself has little marginal value impact. Any recovery trade would require objective evidence—not promotional activity—such as clean filings, stable cash balances, normalized trading volume, and an independent board/auditor upgrade. L'Oréal (OR) has no disclosed economic exposure based on the supplied information; avoid treating the alleged association as a read-through to OR.

Key Decisions for Investors

• Do not initiate a directional long in BYAH on this item; treat it as a liquidity/governance exclusion until the next audited filing verifies revenue, cash, related-party transactions, and auditor status. Time horizon: 1-3 months.
• Avoid a conventional BYAH short absent confirmed borrow availability and a hard locate: low-float securities can gap sharply on retail flows, producing asymmetric squeeze risk despite a negative fundamental outlook.
• Set alerts for late SEC filings, auditor resignation, going-concern language, Nasdaq deficiency notices, or a dilutive financing. Any one would be a stronger 1-6 month downside catalyst than the lead-plaintiff deadline and could support a tightly risk-managed short only if borrow is available.
• Maintain no position in OR based on this news. Reassess only if OR issues a formal statement, disclosed commercial relationship, or regulatory inquiry creates a measurable brand or compliance impact; none is presently evidenced.